ERBB2 and neoplasm: Our early work in HER2- cell lines, MCF7 and MDA-MB-231 demonstrated that silencing EDI3 reduces cell migration [11, 27], a key feature acquired by cancer cells that enables them to leave the primary tumor and reach blood vessels through which they intravasate.